A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases
This study evaluates the safety and efficacy of EBV-specific T-cell lines to treat patients
suffering from high EBV viral titers not responding to standard of care therapies and to
treat EBV-related lymphoma. The study will recruit 6 patients to receive autologous T cells
or a T cell line derived from the patient's allogeneic donor (in the case of stem cell
transplant recipients), and 6 patients to receive a T-cell line prepared from a matched or
partially matched related donor.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society